Simris Alg AB (publ) (SIMRIS-B.ST)
SEK 0.07
(-1.75%)
SEK 0.07
(-1.75%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -36.63 Million SEK | -51.81% |
| 2022 | -24.65 Million SEK | 14.76% |
| 2021 | -28.92 Million SEK | -22.09% |
| 2020 | -23.69 Million SEK | 3.78% |
| 2019 | -24.62 Million SEK | -8.62% |
| 2018 | -22.67 Million SEK | -0.27% |
| 2017 | -22.6 Million SEK | -20.54% |
| 2016 | -18.75 Million SEK | -62.02% |
| 2015 | -11.57 Million SEK | -36.34% |
| 2014 | -8.49 Million SEK | -113.46% |
| 2013 | -3.97 Million SEK | -39.48% |
| 2012 | -2.85 Million SEK | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q1 | -9.03 Million SEK | -2.54% |
| 2024 Q2 | -9.94 Million SEK | -8.69% |
| 2023 Q1 | -9.59 Million SEK | 0.37% |
| 2023 Q3 | -8.04 Million SEK | 22.04% |
| 2023 Q2 | -10.31 Million SEK | -7.5% |
| 2023 FY | -37.43 Million SEK | -51.81% |
| 2023 Q4 | -8.81 Million SEK | -9.59% |
| 2022 FY | -24.65 Million SEK | 14.76% |
| 2022 Q2 | -4.76 Million SEK | -15.03% |
| 2022 Q3 | -6.11 Million SEK | -28.28% |
| 2022 Q4 | -9.63 Million SEK | -57.5% |
| 2022 Q1 | -4.14 Million SEK | -6.07% |
| 2021 Q3 | -10.7 Million SEK | -56.04% |
| 2021 Q1 | -7.46 Million SEK | -4.13% |
| 2021 Q2 | -6.85 Million SEK | 8.09% |
| 2021 FY | -28.92 Million SEK | -22.09% |
| 2021 Q4 | -3.9 Million SEK | 63.49% |
| 2020 Q1 | -6.85 Million SEK | -11.98% |
| 2020 FY | -23.69 Million SEK | 3.78% |
| 2020 Q3 | -4.57 Million SEK | 10.35% |
| 2020 Q2 | -5.09 Million SEK | 25.66% |
| 2020 Q4 | -7.16 Million SEK | -56.77% |
| 2019 Q4 | -6.12 Million SEK | 4.24% |
| 2019 Q3 | -6.39 Million SEK | 9.9% |
| 2019 Q2 | -7.09 Million SEK | -41.81% |
| 2019 Q1 | -5 Million SEK | 26.08% |
| 2019 FY | -24.62 Million SEK | -8.62% |
| 2018 Q1 | -5.57 Million SEK | 13.05% |
| 2018 Q3 | -5.49 Million SEK | -13.85% |
| 2018 Q4 | -6.77 Million SEK | -23.17% |
| 2018 FY | -22.67 Million SEK | -0.27% |
| 2018 Q2 | -4.82 Million SEK | 13.33% |
| 2017 FY | -22.6 Million SEK | -20.54% |
| 2017 Q4 | -6.4 Million SEK | -12.58% |
| 2017 Q3 | -5.69 Million SEK | -14.25% |
| 2017 Q2 | -4.98 Million SEK | 9.86% |
| 2017 Q1 | -5.52 Million SEK | 16.12% |
| 2016 Q1 | -4.58 Million SEK | -49.87% |
| 2016 Q2 | -4.27 Million SEK | 6.74% |
| 2016 Q3 | -3.3 Million SEK | 22.73% |
| 2016 FY | -18.75 Million SEK | -62.02% |
| 2016 Q4 | -6.58 Million SEK | -99.37% |
| 2015 Q2 | -3.6 Million SEK | -32.34% |
| 2015 Q3 | -2.18 Million SEK | 39.33% |
| 2015 Q4 | -3.06 Million SEK | -39.92% |
| 2015 Q1 | -2.72 Million SEK | 0.0% |
| 2015 FY | -11.57 Million SEK | -36.34% |
| 2014 FY | -8.49 Million SEK | -113.46% |
| 2013 FY | -3.97 Million SEK | -39.48% |
| 2012 FY | -2.85 Million SEK | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Alligator Bioscience AB (publ) | -248.98 Million SEK | 85.286% |
| Ziccum AB (publ) | -21.56 Million SEK | -69.921% |
| Modus Therapeutics Holding AB (publ) | -16.4 Million SEK | -123.371% |
| BioArctic AB (publ) | 252.64 Million SEK | 114.501% |
| Sprint Bioscience AB (publ) | -845 Thousand SEK | -4235.503% |
| Mendus AB (publ) | -100.65 Million SEK | 63.602% |
| Genovis AB (publ.) | 54.22 Million SEK | 167.562% |
| Intervacc AB (publ) | -93.57 Million SEK | 60.851% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | -15.51 Million SEK | -136.172% |
| Active Biotech AB (publ) | -46.48 Million SEK | 21.188% |
| Magle Chemoswed Holding AB (publ) | 18 Million SEK | 303.426% |
| Bio-Works Technologies AB (publ) | -55.41 Million SEK | 33.892% |
| Aptahem AB (publ) | -10.1 Million SEK | -262.552% |
| Vicore Pharma Holding AB (publ) | -321.5 Million SEK | 88.605% |
| Kancera AB (publ) | -65.04 Million SEK | 43.675% |
| Infant Bacterial Therapeutics AB (publ) | -134.61 Million SEK | 72.786% |
| Fluicell AB (publ) | -26.87 Million SEK | -36.296% |
| Saniona AB (publ) | -81.06 Million SEK | 54.808% |
| Lipigon Pharmaceuticals AB (publ) | -12.37 Million SEK | -196.136% |
| Biovica International AB (publ) | -126.07 Million SEK | 70.941% |
| Spago Nanomedical AB (publ) | -42.5 Million SEK | 13.81% |
| AcouSort AB (publ) | -17.48 Million SEK | -109.498% |
| Xintela AB (publ) | -57.23 Million SEK | 35.995% |
| Abliva AB (publ) | -96.54 Million SEK | 62.055% |
| Egetis Therapeutics AB (publ) | -324.8 Million SEK | 88.721% |
| Karolinska Development AB (publ) | -3.5 Million SEK | -945.221% |
| OncoZenge AB (publ) | -15.9 Million SEK | -130.38% |
| Amniotics AB (publ) | -29.07 Million SEK | -26.01% |
| 2cureX AB (publ) | -36.36 Million SEK | -0.748% |
| CombiGene AB (publ) | -36.3 Million SEK | -0.909% |
| Asarina Pharma AB (publ) | -14.64 Million SEK | -150.239% |
| Calliditas Therapeutics AB (publ) | -384.39 Million SEK | 90.469% |
| Camurus AB (publ) | 532.35 Million SEK | 106.882% |
| Corline Biomedical AB | -1.78 Million SEK | -1948.937% |
| IRLAB Therapeutics AB (publ) | -180.76 Million SEK | 79.733% |
| Isofol Medical AB (publ) | -41.68 Million SEK | 12.11% |
| I-Tech AB | 24.43 Million SEK | 249.928% |
| Hansa Biopharma AB (publ) | -788.49 Million SEK | 95.354% |
| Cyxone AB (publ) | -21.66 Million SEK | -69.129% |
| ExpreS2ion Biotech Holding AB (publ) | -105.96 Million SEK | 65.427% |
| Biosergen AB | -27.26 Million SEK | -34.366% |
| Cantargia AB (publ) | -290.01 Million SEK | 87.368% |
| NextCell Pharma AB | -43.17 Million SEK | 15.142% |
| Xspray Pharma AB (publ) | -180.76 Million SEK | 79.733% |
| Elicera Therapeutics AB (publ) | -17.09 Million SEK | -114.286% |
| Nanologica AB (publ) | -69.96 Million SEK | 47.637% |
| SynAct Pharma AB | -224.49 Million SEK | 83.681% |
| Annexin Pharmaceuticals AB (publ) | -44.17 Million SEK | 17.07% |
| Stayble Therapeutics AB (publ) | -23.95 Million SEK | -52.937% |
| LIDDS AB (publ) | -40.67 Million SEK | 9.93% |
| Lipum AB (publ) | -37.25 Million SEK | 1.662% |
| BioInvent International AB (publ) | -369.94 Million SEK | 90.097% |
| Alzinova AB (publ) | -16.52 Million SEK | -121.735% |
| Oncopeptides AB (publ) | -253.44 Million SEK | 85.545% |
| Pila Pharma AB (publ) | -6.39 Million SEK | -473.026% |
| Guard Therapeutics International AB (publ) | -115.07 Million SEK | 68.164% |
| Scandinavian ChemoTech AB (publ) | -20.13 Million SEK | -81.911% |
| Diamyd Medical AB (publ) | -146.56 Million SEK | 75.005% |
| Xbrane Biopharma AB (publ) | -310.42 Million SEK | 88.198% |
| Ascelia Pharma AB (publ) | -110.91 Million SEK | 66.97% |
| Diagonal Bio AB (publ) | -11.56 Million SEK | -216.747% |